Patents Assigned to Cancer Institute
  • DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230338551
    Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.
    Type: Application
    Filed: June 27, 2023
    Publication date: October 26, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Dennis Dobrovolsky, Hai-Tsang Huang
  • QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES
    Publication number: 20230339865
    Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).
    Type: Application
    Filed: June 3, 2021
    Publication date: October 26, 2023
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Steven P. Treon, Sara Jean Buhrlage, Guang Yang, Jinhua Wang, Li Tan, Zachary R. Hunter
  • TR-FRET BASED ASSAY FOR DETECTION OF ANTIBODIES IN SEROLOGICAL SAMPLES
    Publication number: 20230341394
    Abstract: The present invention relates to a homogeneous, time resolved, Förster resonance energy transfer (TR-FRET)-based method for detection of SARS-CoV-2, SARS CoV-1, and MERS-CoV antibodies in a patient fluid sample.
    Type: Application
    Filed: August 16, 2021
    Publication date: October 26, 2023
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Eric Fischer, Radoslaw Nowak, Hong Yue, Daan Overwijn, Ralph Mazitschek, Neil Connor Payne
  • POTENT AND SELECTIVE COVALENT INHIBITORS OF SERINE-ARGININE PROTEIN KINASE (SRPK) 1 AND SRPK2 AND USES THEREOF
    Publication number: 20230331721
    Abstract: Disclosed are to compounds, compositions, and methods for treating diseases or conditions mediated by aberrant serine-arginine protein kinase (SRPK) 1 and SRPK2 activity.
    Type: Application
    Filed: October 5, 2021
    Publication date: October 19, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher
  • Reagents and methods for analysis of proteins and metabolites targeted by covalent probes
    Patent number: 11789025
    Abstract: The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: October 17, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jarrod A Marto, Scott B Ficarro, Guillaume Adelmant
  • MEK1 mutation conferring resistance to RAF and MEK inhibitors
    Patent number: 11789022
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: October 17, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • C-RAF mutants that confer resistance to RAF inhibitors
    Patent number: 11788151
    Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: October 17, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
  • LIGANDS TO CEREBLON (CRBN)
    Publication number: 20230312575
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Application
    Filed: November 11, 2022
    Publication date: October 5, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • Dihydrooxadiazinones
    Patent number: 11773070
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: October 3, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Small molecule degraders of polybromo-1 (PBRM1)
    Patent number: 11771697
    Abstract: The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 3, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric Fischer, Nathanael Gray, Radoslaw Nowak, Katherine Donovan, Tinghu Zhang, Yao Liu
  • TEMOZOLOMIDE ANALOGS AND METHODS OF USE
    Publication number: 20230303577
    Abstract: Disclosed herein are compounds and methods for treating cancer, such as glioblastomas.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 28, 2023
    Applicant: St. John's Cancer Institute
    Inventors: Venkata Yenugonda, Santosh Kesari
  • Acrylamide copolymerization for sequestration and production of single-stranded nucleic acid
    Patent number: 11767523
    Abstract: Provided herein, in some embodiments, are methods, compositions and kits for large-scale production of long single-stranded DNA in solution.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 26, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Elisha Krieg, William M. Shih
  • Compositions and methods for induced brown fat differentiation
    Patent number: 11766471
    Abstract: The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm16 and C/EBP? activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm16 and C/EBP? expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm16 and C/EBP? expression and/or activity.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 26, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Shingo Kajimura
  • ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USING SAME
    Publication number: 20230295308
    Abstract: Described and featured herein are antagonistic biparatopic antibodies that specifically bind and inhibit an FGF receptor (e.g., FGFR2) and methods of using such antibodies for the treatment of cancers, including Cholangiocarcinoma (CCAs).
    Type: Application
    Filed: June 2, 2021
    Publication date: September 21, 2023
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Saireudee CHATURANTABUT, William SELLERS
  • NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN ACUTE MYELOID LEUKEMIA
    Publication number: 20230293478
    Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: May 12, 2021
    Publication date: September 21, 2023
    Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer Institute
    Inventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
  • COMPOSITIONS AND METHODS COMPRISING DIGITAL SIGNATURES TO PREDICT RESPONSE AND RESISTANCE TO TARGETED THERAPY AND IMMUNOTHERAPY
    Publication number: 20230295736
    Abstract: The present invention relates to gene expression signatures that predict response and resistance to targeted therapy and immunotherapy.
    Type: Application
    Filed: October 19, 2022
    Publication date: September 21, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Xiaole Liu, Peng Jiang
  • COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20230287510
    Abstract: As described below, the present invention features compositions, panels of biomarkers, and methods for characterizing chronic lymphocytic leukemia (CLL) for prognosis and selection of a subject for a treatment and/or inclusion in a clinical trial.
    Type: Application
    Filed: August 9, 2021
    Publication date: September 14, 2023
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Catherine J. WU, Gad GETZ, Binyamin A. KNISBACHER, Ziao LIN, Cynthia K. HAHN
  • Compositions and methods for transient gene therapy with enhanced stability
    Patent number: 11753434
    Abstract: The present invention provides circularized RNA and methods of making, purifying, and using same.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 12, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Michael Solomon Goldberg, Eliese Carmona
  • Containers for a small volume of liquid target material for irradiation in a cyclotron
    Patent number: 11749420
    Abstract: Devices, systems, and methods for efficiently preparing and containing a small volume of liquid target material for irradiation by a cyclotron are provided. In various embodiments, a device includes a housing having a chamber and the housing has a top surface that is substantially flat. The chamber has a substantially flat base and a wall having a first portion extending from the base with a first radius of curvature and a second portion extending from the first portion having a second radius of curvature that is less than the first radius. The chamber also includes an inlet aperture, an outlet aperture, and a lip having a second surface that is substantially flat and recessed from the first surface. In various embodiments, the device includes a heat sink including a plurality of parallel fins disposed around the chamber.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: September 5, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Erol Bars
  • Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
    Patent number: 11740242
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1 in combination with an immunotherapy.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: August 29, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Adrienne Long